Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Products under Development by Stage of Development | 7 | 1 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Products under Development by Therapy Area | 8 | 1 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Products under Development by Indication | 9 | 1 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Products under Development by Companies | 12 | 2 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Therapeutics Assessment | 14 | 5 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 2 |
| Assessment by Route of Administration | 17 | 1 |
| Assessment by Molecule Type | 18 | 1 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Drug Profiles | 19 | 8 |
| AUT-00063 Drug Profile | 19 | 2 |
| AUT-00206 Drug Profile | 21 | 1 |
| AUT-1 Drug Profile | 22 | 1 |
| AUT-3 Drug Profile | 23 | 1 |
| AUT-6 Drug Profile | 24 | 1 |
| AUT-9 Drug Profile | 25 | 1 |
| Small Molecules to Block Kv3.1 for Fragile X Syndrome Drug Profile | 26 | 1 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Dormant Projects | 27 | 1 |
| Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Featured News &Press Releases | 28 | 3 |
| Aug 01, 2016: Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia | 28 | 1 |
| Jun 04, 2014: Autifony Therapeutics awarded 2.2 million to progress first-in-classdrug for tinnitus into Phase IIa study | 28 | 1 |
| Jun 04, 2013: Autifony Therapeutics Initiates Phase I Trial Of AUT-00063 For Treatment Of Hearing Loss And Tinnitus | 29 | 2 |
| Appendix | 31 | 2 |
| Methodology | 31 | 1 |
| Coverage | 31 | 1 |
| Secondary Research | 31 | 1 |
| Primary Research | 31 | 1 |
| Expert Panel Validation | 31 | 1 |
| Contact Us | 31 | 1 |
| Disclaimer | 32 | 1 |